Resistance-Associated变体在HCV基因型1的人口

丙肝病毒直接作用抗病毒药物治疗(DAAs)短时间内非常有效的很少有副作用。然而,并不是所有的病人都可以用DAAs,聚乙二醇干扰素和利巴韦林是需要一些基因型。基础正确因此仍是治疗选择的支柱之一。按实际使用量付费给越来越多的进入市场的检测resistance-associated变体(红光)正变得越来越重要,进一步完善和优化药物治疗。在这项研究中我们专门研究了红光出现在全球流行的HCV基因型(GT1)。110 EDTA-plasma和亚洲慢性丙肝患者的血清样本GT1a (n = 56)或GT1b (n = 54)感染被纳入本研究。我们使用一种新颖的自动下一代测序(门店)的集成的工作流,组成的机器人平台,RNA提取和图书馆准备包(圣淘沙岛平方HCV基因分型试验)、离子激流深度测序和软件。该系统基于专有软件生成一个自动报告。测序数据分析包括136种已知NS3的红光,NS5A和NS5B基因。52.7%(58/110)的丙肝病毒GT1a和GT1b菌株携带1或多个红光在23个位置在所有目标基因。 An unequal distribution of 4 mutations in the GT1 subtypes was observed. The frequency of the Q80K mutation (NS3) was 25%(14/56) in GT1a and 1.9%(1/54) in GT1b while mutations Q54H and Y93H (NS5A) were prevalent in GT1b at 42.6%(23/54) and 18.5%(10/54) respectively. Y93H was detected in GT1a at 1.8%(1/56). Mutation V499A in NS5B was only found in GT1b at 25.9%(14/54), but not in GT1a. In conclusion, beyond the crucial role of accurate HCV genotyping detection of RAVs by NGS across drug target genes is becoming increasingly important for fine-tuning of HCV treatment. A combined approach by a newly developed NGS-based system can help to streamline generation of relevant pre-treatment information.